Učitavanje...
Discovery of IDO1 inhibitors: from bench to bedside
Small molecule inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) are emerging at the vanguard of experimental agents in oncology. Here pioneers of this new drug class provide a bench-to-bedside review on preclinical validation of IDO1 as a cancer therapeutic target and on the discovery and developm...
Spremljeno u:
| Izdano u: | Cancer Res |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6021761/ https://ncbi.nlm.nih.gov/pubmed/29247038 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-2285 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|